Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Three-Part, Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Adaptive Safety, Pharmacokinetics, and Preliminary Efficacy Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair

Next Previous
Trial Profile

A Three-Part, Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Adaptive Safety, Pharmacokinetics, and Preliminary Efficacy Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vocacapsaicin (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Concentric Analgesics

Most Recent Events

  • 02 Apr 2022 Primary endpoint (Pain -measured using a numerical rating score (NRS) with activity and ambulation and at rest.) has not been met as per results presented at 47th Annual Regional Anesthesiology and Acute Pain Medicine Meeting in Las Vegas, Nevada
  • 02 Apr 2022 Primary endpoint (Pain- measured using a numerical rating score (NRS) with activity coughing) has been met as per results presented at 47th Annual Regional Anesthesiology and Acute Pain Medicine Meeting in Las Vegas, Nevada
  • 02 Apr 2022 Results presented at 47th Annual Regional Anesthesiology and Acute Pain Medicine Meeting in Las Vegas, Nevada

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top